retatrutide mechanism triple agonist gip glp-1 glucagon receptor Beyond GLP- 1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based Understanding the Next-Gen Weight Loss

The main inflammatory mediator is histamine, responsible for the sudden outbreak of swollen bumps or plaques on the skin (161), and a similar role is played by PGD2

Why should patients have to feel sick to their stomachs for the privilege of having their disease treated

The current study Study author Yuya Koide and his colleagues wanted to explore how individuals with type 2 diabetes respond to GLP-1RAs therapy (Koide et al., 2025)

Western blotting Sample preparation Pulverized liver tissue (20 mg) was homogenized in ice cold 1x RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate (SDS), pH 8) using a glass dounce homogenizer